

## FIȘA DE VERIFICARE

a îndeplinirii standardelor minime pentru participarea la concursul de ocupare a postului didactic de CONFERENȚIAR  
UNIVERSITAR în cadrul U.M.F. "Carol Davila" din București

Facultatea de Medicină, Facultatea de Farmacie, Facultatea de Moașe și Asistență Medicală

## I. Date despre candidat

Nume: PREOTESCU

Prenume: LILIANA LUCIA

## II. Date numerice privind îndeplinirea standardelor minime necesare și obligatorii prevăzute în Ordinul Ministrului Educației Naționale și Cercetării Științifice nr. 6129/20.12.2016

## 1. Articole publicate în reviste cotate ISI Web of Science Clarivate, în calitate de autor principal

Criteriul	Standard minim	Realizat
Număr articole ISI <i>in extenso</i> în reviste cotate ISI Web of Science Clarivate, în calitate de autor principal	6	6

**Lista articolelor ISI publicate în calitate de autor principal: autori, titlu articol, revistă, an, volum, pagini, factor de impact, pentru realizarea standardelor minime.**

Nr. Crt.	Autori	Tip autor prim, contribuție egală, ultim, corespondent și link către revistă sau către documentul scanat în care este menționată explicit contribuția egală sau statutul de autor corespondent	Titlu articol	Revista	An	Volum	Pagini	Factor de impact
AP-1	Săndulescu O, Streinu- Cercel A, Moțoi MM, Streinu- Cercel A, Preoțescu LL.	Ultim autor	Syndromic Testing in Infectious Diseases: From Diagnostic Stewardship to Antimicrobial Stewardship.	Antibiotics (Basel).	2023	12	ID articol: 6	5.222
AP-2	Sandulescu O, Viziteu I, Streinu- Cercel A, Miron VD, Preoțescu LL, Chirca N.	Contributii egale	Novel antimicrobials, drug delivery systems and antivirulence targets in the pipeline—from bench to bedside.	Appl Sci.	2022	12	ID articol: 11615	2.838

	Albu SE, Craiu M, Streinu- Cercel A.							
AP-3	Kim JY#, Săndulescu O#, Preotescu LL#, Rivera- Martínez NE, Dobryanska M, Birlutiu V, Miftode EG, Gaibu N, Caliman- Sturdza O, Florescu SA, Shi HJ, Streinu- Cercel A, Streinu- Cercel A, Lee SJ, Kim SH, Chang I, Bae YJ, Suh JH,	Co-prim autor	Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to- Moderate Coronavirus Disease 2019.	Open Forum Infect Dis.	2022	9	ID articol: ofac406	4.433

	Chung DR, Kim SJ, Kim MR, Lee SG, Park G, Eom JS. A							
AP-4	Streinu- Cercel A#, Săndulescu O#, Preotescu LL#, Kim JY, Kim YS, Cheon S, Jang YR, Lee SJ, Kim SH, Chang I, Suh JH, Lee SG, Kim MR, Chung DR, Kim HN, Streinu- Cercel A, Eom JS.	Co-prim autor	Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Trial in Outpatients With Mild-to- Moderate Coronavirus Disease 2019.	Open Forum Infect Dis	2022	9	ID articol ofac053	4.433
AP-5	Nițescu M, Văjăitu C,	Contributii egale	Non-invasive quantification of liver fibrosis regression	Rom J Lab Med.	2017	25	355- 363	0.400



	Săndulescu O, Streinu- Cercel A, Pițigoi D, Preoțescu LL, Streinu- Cercel A.		following successful treatment of chronic hepatitis C with direct acting antivirals.					
AP-6	Fronie A, Bunget A, Afrem E, Preoțescu LL, Corlan Pușcu D, Streba L, Mogoantă L, Dumitrescu D.	Contributii egale	Squamous cell carcinoma of the oral cavity: clinical and pathological aspects.	Rom J Morphol Embryol.	2013	54	343- 348	0.723

**Criteriu îndeplinit:**

DA     NU

**2. Articole publicate în reviste cotate ISI Web of Science Clarivate, în calitate de coautor**

Criteriul	Standard minim	Realizat
-----------	----------------	----------

Număr articole publicate în reviste cotate ISI Web of Science Clarivate, în calitate de coautor	3	29
---	---	----

**Lista articolelor ISI publicate în calitate de coautor: autori, titlu articol, revistă, an, volum, pagini, factor de impact, pentru realizarea standardelor minimele.**

Nr. Crt.	Autori	Titlu articol	Revista	An	Volum	Pagini	Factor de impact
CA-1	Haeuser E, Serfes AL, Cork MA, .... Preotescu L, ...., Dwyer- Lindgren L	Local Burden of Disease sub-Saharan Africa HIV Prevalence Collaborators. Mapping age- and sex- specific HIV prevalence in adults in sub-Saharan Africa,	BMC Med	2022	20	ID: 488	11.8
CA-2	Șogorescu AȘ, Viziteu I, Streinu-Cercel A	Treatment initiation or switch to BIC/FTC/TAF - real-world safety and	Germs	2021	11	512-522	2.83

		efficacy data from two HIV centers in Romania.					
CA-3	Kocarnik JM, Compton K, , <b>Preotescu L,</b> ...Force LM	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study	JAMA Oncol.	2022	8	420-444	33,012
CA-4	Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F,	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial	Nat Med.	2021	27	1825-1835	87,241

Flores- Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S; ARREST investigator study group							
---	--	--	--	--	--	--	--



	(Preotescu L et al), Sanyal AJ						
CA-5	Abbafati C, ..., Preotescu L, et al	Five insights from the Global Burden of Disease Study 2019	Lancet	2020	396	1135-1159	79.323
CA-6	Wang H, ..., Preotescu L, et al	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019	Lancet	2020	396	1160-1203	79.323

CA-7	Abbfati C, ...,PreotescuL, et al.	Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.	Lancet	2020	396	1204-1222	79,323
CA-8	Deshpande A, ...Preotescu L., et	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000-17.	Lancet Glob Health	2020	8	162-185	26.763
CA-9	Wiens KE, ..., Preotescu L, et al	Local Burden of Disease Diarrhoea Collaborators	Lancet Glob Health	2020	8	038-060	26.763

CA-10	Kinyoki DK, ... Preotescu L	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017	Nat Med	2020	26	750-759	53.440
CA-11	Reiner RC Jr., Preotescu L, et al	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017	Lancet	2020	395	1779-1801	79.323
CA-12	Niehus R, van Kleef E, Mo Y, Turlej-	Quantifying antibiotic impact on within-patient dynamics of extended-	E-life	2020	9	e 49206	8.146

	Rogacka A, Lammens C, Carmeli Y, Goossens H, Tacconelli E, Carevic B, Preotescu L, Malhotra- Kumar S, Cooper BS	spectrum beta-lactamase resistance					
CA- 13	Kinyoki DK, ..., Preotescu L, et al.	Mapping local patterns of childhood overweight and wasting in low- and middle- income countries between 2000 and 2017	Nat Med	2020	26	750-75953.44	



CA-14	Boccaro F, Kumar PN, Caramelli B, Calmy A, López JAG, Bray S, Cyrille M, Rosenson RS; Baker D, ..., Preotescu LL, et al	Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study	J Am Coll Cardio	2020	26	2570-2584	24.093
CA-15	Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM,	Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection	N Engl J Med	2020	382	1232-1243	91.253

	Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M						
CA-16	Tacconelli E, Górska A, De Angelis G, Lammens C, Restuccia G,	Estimating the association between antibiotic exposure and colonization with extended-spectrum $\beta$ - lactamase-producing Gram-	Clin Microbiol Infect.	2020	26	87-94	8.067

	Schrenzel J, Huson DH, Carević B, Preoteşcu L, Carmeli Y, Kazma M, Spanu T,	negative bacteria using machine learning methods: a multicentre, prospective cohort stud					
CA- 17	Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I,	Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo- controlled, non-inferiority, randomised phase 3 trials	Lancet Infect Dis	2019	19	265-274	24,446

	Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH						
CA- 18	Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Preotescu L et al	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI- 2): week 48 results from two multicentre, double-blind,	Lancet	2019	393	143-155	59.102



		randomised, non-inferiority, phase 3 trials					
CA- 19	Meletiadis J, Turlej- Rogacka A, Lerner A, Adler A, Tacconelli E, Mouton JW; the SATURN Diagnostic Study Group (Malhotra- Kumar S, Goossens H, Lammens C, Percia S, De	Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone	Antimicrob Agents Chemother	2017	61	e00473-17	4.256

	Angelis G, Restuccia G, Preotescu L., Popoiu M, Carevic B, Tosic T, Harbarth S, Carmeli Y						
CA- 20	Streinu-Cercel A, Săndulescu O, Manolache D, Stoica MA, Preotescu LL, Streinu-Cercel A.	Drug-drug interaction (DDI) tools – useful versus mandatory in the management of difficult to treat patients with chronic HCV infection.	Farmacia	2017	65	136-141	1.507

CA-21	Streinu-Cercel A, Sandulescu O, Ceapraga G, Manolache D, Stoica MA, Preotescu LL, Streinu-Cercel A	Prevalence of osteo-renal impairment in the Romanian HIV cohort	BMC Infect Dis	2016	16	11-16	2.768
CA-22	Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S,	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort	PLoS One	2016	11	e0151703	2.806

	Bakalos G, Hassanein T; GUARD-C Study Group (Basho J, Shabanaj G, Harxhi A, [...], Preotescu L, et al						
CA- 23	Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-	Elafibranor, an Agonist of the Peroxisome Proliferator- Activated Receptor- $\alpha$ and - $\delta$ , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening	Gastroenterology	2016		doi: 10.1053/j.gastro. 2016.01.038.	18.392



	Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee Q, Hum D, Hanf R, Roudot A, Megnier S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group						
CA- 24	Lawitz E, Makara M, Akarca US,	Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label	Gastroenterology	2015	149	971-980	18.187

	Thuluvath PJ, <b>Preotescu LL,</b> Varunok P, Morillas RM, Hall C, Mobashery N, Redman R, Pilot-Matias T, Vilchez RA, Hézode C	Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis					
CA- 25	Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V,	Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study	Lancet HIV	2015	2	36	e127- 8.364

	Givens N, de Oliveira CF, Brennan C; FLAMINGO study team						
CA-26	Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C,	48 week results from the randomised open-label phase 3b study	Lancet	2014	383	2222-31	45.217

	<p>Fujiwara T,  Min S;  ING114915  Study Team.  Once-daily  dolutegravir  versus  darunavir plus  ritonavir in  antiretroviral-  naive adults  with HIV-1  infection  (FLAMINGO)</p>						
CA-27	<p>Ratzju V,  Bedossa P,  Francque SM,</p>	<p>Lack of Efficacy of an  Inhibitor of PDE4 in Phase 1</p>	<p>Clin Gastroenterol  Hepatol.</p>	2014	12	1724-30	7.896

	Larrey D, Aithal GP, Serfaty L, Voiculescu M, <b>Preotescu L,</b> Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K	and 2 Trials of Patients With Nonalcoholic Steatohepatitis					
CA- 28	Gheorghe L, Iacob S, Simionov I, Caruntu F,	A Real Life Boceprevir Use in Treatment-Experienced HCV Genotype 1 Patients with Advanced Fibrosis	J Gastrointestin Liver Dis.	2014	23	45-50	2.202



	Arama V, Preotescu L, Stefan I, Rugina S, Rednic N. A Real Life Boceprevir Use in Treatment- Experienced HCV Genotype 1						
CA- 29	Cork, Michael A.; Henry, Nathaniel J. Preotescu LL ... Dwyer-	Mapping subnational HIV mortality in six Latin American countries with incomplete vital registration systems	BMC Medecine	2021	19		11.8

	Lindgren, Laura						
--	--------------------	--	--	--	--	--	--

**Criteriu îndeplinit:**

DA     NU

**3. Factorul cumulat de impact pentru articolele publicate ca autor principal în reviste cotate ISI (FCIAP)**

<b>Criteriul</b>	<b>Standard minim</b>	<b>Realizat</b> ( <i>suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI Web of Science Clarivate</i> )
<b>(ISI) Factor cumulat de impact autor principal</b>	6	<b>18.049</b>

**Lucrările care sunt luate în considerare pentru calculul sumei factorului cumulat de impact pentru articolele publicate ca autor principal în reviste cotate ISI**

<b>Nr. Crt.</b>	<b>Autori</b>	<b>Titlu articol</b>	<b>Revista</b>	<b>An</b>	<b>Volum</b>	<b>Pagini</b>	<b>Factor de impact</b>
LI.	Săndulescu O, Streinu-Cercel A, Moțoi MM,	Syndromic Testing in Infectious Diseases: From Diagnostic	Antibiotics (Basel).	2023	12	ID articol: 6	5.222

	Streinu-Cercel A, Preotescu LL.	Stewardship to Antimicrobial Stewardship.					
L2.	Novel antimicrobials, drug delivery systems and antivirulence targets in the pipeline—from bench to bedside.	Appl Sci.	2022	12	ID articol: 11615	2.838	
L3	Kim JY#, Săndulescu O#, Preotescu LL#, Rivera-Martínez NE, Dobryanska M, Birlutiu V, Miftode EG, Gaibu N, Caliman-Sturdza O, Florescu SA, Shi HJ, Streinu-Cercel A, Streinu-Cercel A, Lee SJ, Kim SH, Chang I, Bae YJ, Suh JH, Chung DR, Kim SJ, Kim MR, Lee SG, Park G, Eom JS. A	Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.	Open Forum Infect Dis.	2022	9	ID articol: ofac406	4.433

L.4	Streinu-Cercel A#, Săndulescu O#, Preotescu LL#, Kim JY, Kim YS, Cheon S, Jang YR, Lee SJ, Kim SH, Chang I, Suh JH, Lee SG, Kim MR, Chung DR, Kim HN, Streinu-Cercel A, Eom JS.	Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.	Open Forum Infect Dis	2022	9	ID articol ofac053	4.433
L.5	Nițescu M, Văjăitu C, Săndulescu O, Streinu-Cercel A, Pițigoi D, Preotescu LL, Streinu-Cercel A.	Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals.	Rom J Lab Med.	2017	25	355-363	0.400
L.6	Fronie A, Bunget A, Afrem E, Preotescu LL, Corlan Pușcu D, Streba L, Mogoantă L, Dumitrescu D.	Squamous cell carcinoma of the oral cavity: clinical and pathological aspects.	Rom J Morphol Embryol.	2013	54	343-348	0.723

Criteria îndeplinit.  DA

NU



#### 4. Indexul Hirsch

Criteriul	Standard minim	Realizat
Index Hirsch	4	13

#### Lucrările care sunt luate în considerare pentru calculul indexului Hirsch (conform Web of Science – Core Collection):

Nr. Crt.	Autori	Titlu articol	Revista	An	Volum	Pagini	Numărul de citări
L1.	Streinu-Cercel A#, Săndulescu O#, Preotescu LL#, Kim JY, Kim YS, Cheon S, Jang YR, Lee SJ, Kim SH, Chang I, Suh JH, Lee SG, Kim MR, Chung DR, Kim HN, Streinu-Cercel A, Eom JS.	<i>Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019</i>	Open Forum Infect Dis	2022	9	ID articol ofac053	9
L2.	Kocarnik JM, Compton K, , <b>Preotescu L</b> , ...Force LM	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study	JAMA Oncol.	2022	8	420-444	123
L3.	Cork, Michael A.; Henry, Nathaniel J., Preotescu L	Mapping subnational HIV mortality in six Latin American countries with	BMC Medecine	2021	19		45



	... Dwyer-Lindgren, Laura	incomplete vital registration systems					
L4	Abbafati C, ..., Preotescu L, et al	Five insights from the Global Burden of Disease Study 2019	Lancet	2020	396	1135-1159	303
L5	Wang H, ..., Preotescu L, et al	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019	Lancet	2020	396	1160-1203	315
L6	Abbafati C, ...,PreotescuL, et al.	Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.	Lancet	2020	396	1204-1222	1551
L7	Wiens KE, ..., Preotescu L, et al	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000-17..	Lancet Glob Health	2020	8	e1038-e1060	11
L8	Deshpande A, ...Preotescu L, et	Mapping geographical inequalities in access to drinking water and sanitation facilities	Lancet Glob Health	2020	8	162-185	36

		in low-income and middle-income countries, 2000-17.					
L9	Reiner RC Jr., Preotescu L, et al	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017	Lancet	2020	395	1779-1801	40
L10	Niehus R, van Kleef E, Mo Y, Turlej- Rogacka A, Lammens C, Carmeli Y, Goossens H, Tacconelli E,	Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance	E-life	2020	9	e 49206	9

	Carevic B, Preotescu L,						
L11	Kinyoki DK, ..., Preotescu L, et al.	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017	Nat Med	2020	26	750- 75953.44	25
L12	Tacconelli E, Górska A, De Angelis G, Lammens C, Restuccia G, Schrenzel J, Huson DH, Carević B, Preotescu L, Carmeli Y, Malhotra-	Estimating the association between antibiotic exposure and colonization with extended- spectrum $\beta$ - lactamase-producing Gram-negative bacteria using machine learning methods: a multicentre, prospective cohort stud	Clin Microbiol Infect.	2020	26	87-94	17

	Kumar S, Gladstone BP						
L13	Gerding DN, Cornely OA, Kracker H, Marrast AC, Talbot GH, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J,	Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials	Lancet Infect Dis	2019	19	265-274	25
L14	Streinu-Cercel A, Săndulescu O, Manolache	Drug-drug interaction (DDI) tools – useful versus mandatory in the management of difficult to treat	Farmacia	2017	65	136-141	3



	D, Stoica MA, Preoșescu LL, Streinu-Cercel A.	patients with chronic HCV infection.					
L15	Nișescu M, Văjăitu C, Săndulescu O, Streinu-Cercel A, Pițigoi D, Preoșescu LL, Streinu-Cercel A.	Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals.	Rom J Lab Med	. 2017	25	355-363	2
L16	Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML,	Impact of Safety- Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV- Infected Patients: Results from the GUARD-C Cohort	PLoS One	2016	11	e0151703	4



	Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group (Basho J, , Harxhi A, [...]), Preotescu L, et al						
L17	Streinu-Cercel A, Sandulescu O, Ceapraga G, Manolache D, Stoica MA, Preotescu LL, Streinu-Cercel A	Prevalence of osteo- renal impairment in the Romanian HIV cohort	BMC Infect Dis	2016	16	11-16	5
L18	Ratzu V, Bedossa P, Francque SM, Voiculescu M, <b>Preotescu L,</b>	Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis	Clin Gastroenterol Hepatol.	2014	12	1724-30	33

	Nevens F, De Lédinghen V,						
L19	Asselah, Tarik; Jensen, Preotescu L, Donald M. ... Ferenci, Peter	Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naive Patients: Pooled Analysis of Phase III Studies	Gastroenterology	2014	146	S-977	2
L20	Sarrazin, Christoph; Castelli, Preotescu L, Francesco ... Mensa, Federico J.	HCVerso 1: A phase III study of faldaprevir (FDV) plus deleobuvir (DBV) and ribavirin (RBV) for chronic HCV genotype (GT)-1b infection in treatment-naive patients	Hepatology	2014	1		3
L21	Gheorghe L, Iacob S, Preotescu L, Stefan I,	A Real Life Boceprevir Use in Treatment-Experienced HCV Genotype 1 Patients with Advanced Fibrosis	J Gastrointestin Liver Dis.	2014	23	45-50	4

	Goldis A, Brisic C, Rugina S, et al						
L22	Fronie A, Bunget A, Afrem E, Preotescu LL, Corlan Puşcu D, Streba L.,	Squamous cell carcinoma of the oral cavity: clinical and pathological aspects.	Rom J Morphol Embryol.	2013	54	343-348	10
L23	Dieterich, Douglas; Asselah, Tarik ... Boecher, Preotescu L. Wulf O. et al	Silen-C3: treatment for 12 or 24 weeks with bi201335 Combined with peginterferon alfa-2a and ribavirin (p/r) in Treatment-naive patients with chronic genotype-1 hcv Infection	Hepatology	2011	1		10
L24	Zeuzem, Stefan; Soriano, Vincent, Preotescu L, ...	Virologic response to an interferon-free regimen of Bi201335 and bi207127, with and without ribavirin, in Treatment-naive patients with chronic genotype-1 hcv	Hepatology	2011	2		10

	Mensa, Federico J.	Infection: week 12 interim results of the sound-c2 study					
L25	Sulkowski, M. S.; Ceasu, E, Preotescu L. ... Steinmann, G.	Silen-C1: sustained virologic response (svr) and safety of Bi201335 combined with peginterferon alfa-2a and ribavirin (p/r) in treatment-naive patients with chronic genotype 1 Hcv infection	Hepatology	2011	1		35
L26	Sulkowski, M. S.; Bourliere, M., Preotescu L.,... Steinmann, G.	<i>Silen-C2: sustained virologic response (svr) and safety of Bi201335 combined with peginterferon alfa-2a and ribavirin (p/r) in chronic hec genotype-1 patients with non-response To p/r</i>	Hepatology	2011	1		35

**Criteriu îndeplinit:**

DA

NU

Confirm prin prezenta că datele menționate mai sus sunt reale și se referă la propria mea activitate profesională și științifică



Data

12 IAN 2023

Semnătura candidatului

**Note asupra metodei de calcul:**

1. va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science Clarivate, Core Collection, Thomson Reuters, pentru întreaga carieră a candidatului („all years”);
2. o revistă cotate ISI este o revistă pentru care Thomson Reuters calculează și publică factorul de impact în „Journal Citation Reports”;
3. autorul/autorii principali ai unei publicații se consideră a fi oricare dintre următorii:
  - a. primul autor;
  - b. autorul corespondent;
  - c. alți autori, a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent;
  - d. ultimul autor.
4. factorul cumulat de impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP). FCIAP = suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI;
5. vor fi incluse articole originale și reviews; în cazul publicațiilor în reviste cu factor de impact mai mare decât 3, pot fi luate în considerare și alte tipuri de publicații în extenso (nu rezumate)